Buy Ozempic Injection Pen Online
Ozempic Semaglutide Injection is a prescription medication used to treat and manage Type 2 Diabetes. The active ingredient is Semaglutide which copies the action of one of the bodies natural hormones (GLP1).
It is also responsible for making you feel full and as a result, reducing appetite. GLP1/Semaglutide also delays the emptying of your stomach which again goes toward making you feel full for a longer time.
Clinical studies have shown Ozempic Semaglutide injection to be effective and acceptable for use by patients with Type 2 Diabetes. The clinical evidence also suggests that Semaglutide can also help obese patients with weight loss, leaving the patient feeling more satisfied after eating.
This suggests that Semaglutide may be a more potent drug and possibly better suited to those with a higher BMI or who may be classed as obese. The license indication is for type 2 diabetes and studies have looked at weight loss as a secondary endpoint. Clinical trials for which have looked at weight loss as a primary endpoint have recently been completed and are with the regulatory authorities pending a license to treat weight loss and obesity. Prescribing Ozempic for weight loss in the UK is therefore off-license, although clinically justified.
Important to note that this medication is licensed for type-2 diabetes and not licensed as a weight loss medication. Prescribing for weight loss is therefore off-label.
Indications of Ozempic Semaglutide Injection and Limitations
Important Safety Information
- Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a hypersensitivity reaction to semaglutide or to any of the excipients in Ozempic. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with Ozempic.
Warnings and Precautions
- Risk of Thyroid C-Cell Tumors: Patients should be referred to an endocrinologist for further evaluation if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
- Pancreatitis: Acute and chronic pancreatitis have been reported in clinical studies. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic pen injector promptly, and if pancreatitis is confirmed, do not restart.
- Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
- Never Share an Ozempic Pen Between Patients: Ozempic pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.
- Hypoglycemia: Patients receiving Ozempic in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
- Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Ozempic in patients reporting severe adverse gastrointestinal reactions.
- Hypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported in patients treated with Ozempic. If hypersensitivity reactions occur, discontinue use of Ozempic; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist.
- Acute Gallbladder Disease: Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and post marketing. In placebo-controlled trials, cholelithiasis was reported in 1.5% and 0.4% of patients treated with Ozempic 0.5 mg and 1 mg, respectively, and not reported in placebo-treated patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
- The most common adverse reactions, reported in ≥5% of patients treated with Ozempic are nausea, vomiting, diarrhea, abdominal pain, and constipation.
Ozempic Semaglutide Injection Interactions
- When initiating Ozempic, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
- Ozempic causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.
Ozempic Semaglutide Injection For Weight Loss
Whilst Ozempic Semaglutide Injection is being being marketed and licensed for Diabetes, the active ingredient (Semaglutide) has shown to suppress appetite and help the person taking it feel fuller quicker after a meal and for longer. This means that those taking Semaglutide are not just likely to consume less during a meal, feeling fuller for longer would mean being less likely to snack as much between meals. This reduction in appetite may also contribute to patients eating smaller portions than what they’re used to. An overall significantly less calorie deficit would tend to result in patients beginning to lose weight when they start taking Ozempic Semaglutide Injection.
How Effective is Ozempic Semaglutide Injection for Weight Loss?
A number of clinical trials have been carried out to show the effectiveness of Ozempic Semaglutide Injection as a weight loss drug. In one such study, 957 participants had taken part, all with a BMI of 30 or above, over 18 years of age and non-diabetic. The study found that 957 participants with a BMI of 30 kg/m2 or more took part in a clinical trial to test the efficacy of Semaglutide Ozempic as weight loss drug. Eligible participants were adults over the age of 18 years, who did not have diabetes. 37-65% of those taking Semaglutide Ozempic lost an estimated 10% or more body weight across all doses. In comparison, those who took the placebo (non-active medication), the same weight loss was seen in only 10% of those participants.
This study concluded that Ozempic Semaglutide Injection in combination with dietary and physical activity counselling, semaglutide Ozempic was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses.
Ozempic Semaglutide Injection is already available to be prescribed in the UK and is licensed to treat type-2 diabetes under the name of Ozempic. An application has been submitted to the regulatory authorities and in the process of being approved as a weight loss medication in the near future.
Ozempic Semaglutide Injection for sale is approved in the UK and there is sufficient clinical evidence in weight loss. It has been generally well-tolerated by people who do not have Type 2 Diabetes with no new safety concerns arising in the recent clinical trials. An independent prescriber is permitted to prescribe it for weight loss as long as they feel it is clinically appropriate and justified.
How To Take Ozempic Semaglutide Injection
The starting dose of 0.25 mg is a non therapeutic dose.
Ozempic pen is a once weekly pre-filled injectable.
Attach the single-use needle which comes in the box,
Dial the dose to the required level and inject into the stomach or thigh.
Each pen lasts 4 weeks.
Ozempic Semaglutide Injection dose is 0.25 mg once a week for the first 4 weeks. This will give your body a chance to get used to the medicine.
At Week 5, you will increase the dose to 0.5 mg once a week, followed by 1.0mg.
Once you have reached 1.0mg you remain on that for the duration of your treatment.